COVID-19 has raised significant concern regarding its neurological impact, particularly during the early pandemic waves when severe systemic inflammation and neuroimmune dysregulation were more common. Although SARS-CoV-2 has been extensively studied, the precise mechanisms underlying its neurological effects remain incompletely understood, and much of the available evidence is derived from early variants with higher pathogenicity. Current research indicates that neuroinflammatory processes—driven primarily by systemic cytokine elevation, microglial activation, and blood–brain barrier dysfunction—contribute to a wide range of neurological symptoms. Severe complications such as encephalopathy, stroke, and cognitive impairment were predominantly reported in critically ill patients infected with the Wuhan, Alpha, or Delta variants, while such manifestations are considerably less frequent in the Omicron era. Most proposed mechanisms, including ACE2-mediated viral entry into the central nervous system, are supported mainly by experimental or preclinical studies rather than definitive human evidence. Biomarkers such as IL-6 and TNF-α, along with neuroimaging modalities including MRI and PET, offer useful but indirect indicators of neuroinflammation. Therapeutic approaches continue to focus on controlling systemic inflammation through immunomodulatory agents, complemented by targeted non-pharmacological strategies—such as physical rehabilitation, cognitive support, and psychological interventions—for the minority of patients with persistent neurological deficits. Overall, current evidence supports a variant-dependent neuroinflammatory profile and underscores the need for longitudinal, mechanism-focused studies to better characterize long-term neurological outcomes and refine therapeutic strategies.

The deep-seated and multi-faceted cancer, driven by genetic mutations, has remained a major hurdle for both detection as well as therapeutic management. Single-cell RNA sequencing (scRNA-seq) has emerged as a powerful approach for understanding the heterogeneity found in cancer and identifying potential therapeutic targets. In this study, we elucidate its function in the context of laryngeal squamous cell carcinoma (LSCC). In order to explore novel molecular-targeted biomarkers and establish precise monitoring strategies for the diagnosis, and treatment of LSCC based on acute transcriptome screening results by using scRNA-seq data (GSE252490). After data processing, quality control and standardization took place followed by the detection of highly variable genes optimization using principal component analysis. Further cell clustering revealed 12 discrete clusters with unique molecular features. We finally detected 6434 differentially expressed genes (DEGs) by comparing the marker gene with the human homolog. Gene ontology enrichment analysis indicates the biological processes associated with LSCC progression. Protein-protein interaction (PPI) network construction revealed twenty central genes associated with multiple key pathways involved in building up cancer. Pathway enrichment by the KEGG pathway was used to underline the involvement of these centric genes in various cancer-related pathways. Moreover, the evaluation of mRNA expression and clinical prognosis further confirmed their significance in LSCC. Of these genes, CCL3, EPCAM, and IL8 with increased expression levels are linked to the survival rate in LSCC. The present analysis provides insight into the molecular landscape of LSCC, thereby identifying potential candidates for diagnosis and targeted therapy.

Background: Since the 2022 outbreak, the number of Monkeypox cases worldwide has been increasing at an alarming rate. As of August 2024, approximately 99,000 people have been infected with the virus. The severity of this situation is further highlighted by the World Health Organization's (WHO) classification of the Mpox virus as a Public Health Emergency of International Concern (PHEIC) due to the increased fatality rate of approximately 3.6% in clade I. Objectives: Targeting the virus's membrane-bound, enveloped, and extracellular proteins, our goal was to computationally develop and assess a broad-spectrum multi-epitope vaccine that elicits humoral and adaptive immune responses against Monkeypox virus (MPXV) infection. Methods: During an outbreak, a pan-genome-based reverse vaccinology approach can offer rapid, practical solutions to enduring problems in experimental vaccine design. The method involved screening 16 monkeypox genomes to identify viral targets, from which viral proteins were selected based on their antigenicity, location, and solubility. Immunoinformatics methods and algorithms were used to extract the proteins’ putative T-cell and B-cell epitopes, which were combined to form several vaccine constructions. The tertiary structure of the chimeric vaccine construct's interaction with Toll-like receptor 4 (TLR4) was thoroughly assessed using the advanced techniques of molecular docking and molecular dynamics simulation. Results: A pan-genomic analysis identified 80 core genes, which were then screened for proteins suitable for epitope-based vaccine design. From four of these selected proteins, T-cell and B-cell epitopes were extracted to create four distinct vaccine constructs. Appropriate adjuvants and linkers were incorporated into each construct to enhance its potential efficacy. Stability and immunogenicity analyses of each vaccine design yielded promising results. These findings suggest that the vaccine constructs could be effective in preventing monkeypox, warranting further experimental validation and supporting the application of similar strategies to combat other viral illnesses.